Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA.
Department of Hematology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
J Zhejiang Univ Sci B. 2019 May;20(5):391-398. doi: 10.1631/jzus.B1900148.
Sirtuin 1 (SIRT1) is a protein deacetylase, which regulates various physiological activities by deacetylating different protein substrates. An increasing number of studies have revealed critical roles of SIRT1 in different aspects of cancers including metabolism, proliferation, genomic instability, and chemotherapy resistance. Depending on the protein targets in a certain oncogenic context, SIRT1 may play a unique role in each individual blood cancer subtype. Our previous work showed that activation of SIRT1 in primitive leukemia cells of acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML) promotes disease maintenance. On the other hand, an SIRT1 agonist was shown to disrupt maintenance of myelodysplastic syndrome (MDS) stem cells and holds promise as a potential therapeutic approach. Herein, we present a concise summary of the different functions of SIRT1 in hematologic malignancies.
Sirtuin 1（SIRT1）是一种蛋白去乙酰化酶，通过去乙酰化不同的蛋白底物来调节各种生理活动。越来越多的研究揭示了 SIRT1 在癌症的不同方面的关键作用，包括代谢、增殖、基因组不稳定性和化疗耐药性。根据特定致癌环境中的蛋白靶点，SIRT1 在每种个体血液癌亚型中可能发挥独特的作用。我们之前的工作表明，急性髓系白血病（AML）和慢性髓系白血病（CML）原始白血病细胞中 SIRT1 的激活促进了疾病的维持。另一方面，SIRT1 激动剂被证明可以破坏骨髓增生异常综合征（MDS）干细胞的维持，并有望成为一种潜在的治疗方法。本文简要总结了 SIRT1 在血液恶性肿瘤中的不同功能。
